Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16163924 | 0.82 | DRD3 (0.34) | DRD3HTR2AHTR2C | |
| SCHEMBL15347806 | 0.78 | GSK3B (0.45) | CYP1A2CYP2D6 | |
| SCHEMBL295269 | 0.78 | CNR2 (0.46) | DRD3CYP1A2CYP2D6 | |
| SCHEMBL1520672 | 0.75 | HRH3 (0.44) | HTR2AHTR2CHTR2BCYP1A2CYP2D6 | |
| SCHEMBL2540747 | 0.74 | CYP1A2 (0.35) | DRD3CYP1A2 | |
| SCHEMBL5033938 | 0.73 | GSK3B (0.34) | HTR2CHTR2BCYP1A2CYP2D6 | |
| SCHEMBL28449775 | 0.73 | CHRM2 (0.39) | CYP2C19 | |
| SCHEMBL28713607 | 0.73 | TRPM8 (0.46) | HTR2B | |
| SCHEMBL30317690 | 0.73 | AR (0.45) | ARADORA3HSD11B1AKR1C3CYP3A4 | |
| SCHEMBL4125134 | 0.72 | HTR2A (0.34) | DRD3HTR2AHTR2CHTR2BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414063-B2 | Inhibitors of Akt (protein kinase B) | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | ELI LILLY AND COMPANY | 2007-02-22 | — | — | US | disclosed |
| EP-1611105-A1 | ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) | ELI LILLY AND COMPANY (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004094386-A1 | ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | AKT1, AKT2, BRAF | AR 2976/4885ADORA3 4545/4885HSD11B1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.